Medpace Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- August James Troendle
- Full Time Employees
- 5,900
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5375 Medpace Way Cincinnati OH United States of America 45227
- IPO Date
- Aug 11, 2016
- CIK
- 0001668397
- Website
- medpace.com
- Similar Companies
- Business
- Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries; core offerings encompass clinical trial management, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory services including central laboratories, bioanalytical laboratory, imaging core lab, ECG core lab, and Phase I clinical unit; the company operates its proprietary ClinTrak clinical trial management system to integrate study data and enhance efficiency. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace conducts operations across North America, Europe, Latin America, Asia Pacific, South America, Africa, and Australia, with a focus on complex trials in therapeutic areas such as oncology, cardiology, neurology, and infectious diseases, primarily serving small- to mid-sized biotech clients. In recent developments, the company reported record net new business awards of $789.6 million in Q3 2025, a 47.9% increase year-over-year, driving a net book-to-bill ratio of 1.20 and prompting upward revisions to 2025 revenue guidance to $2.48-$2.53 billion, reflecting 17.6%-20.0% growth over 2024 amid strong backlog momentum exceeding $3 billion; Medpace also projects low double-digit revenue growth and high single-digit EBITDA expansion for 2026, supported by strategic emphases on AI-enabled decentralized trials, oncology, and Phase III studies.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
CON or MEDP: Which Is the Better Value Stock Right Now?
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Is It Too Late to Buy Medpace Holdings Inc (MEDP) After 3.9% Rally? GF Value Says Undervalued
Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
CON vs. MEDP: Which Stock Is the Better Value Option?
Why the Market Dipped But Medpace (MEDP) Gained Today
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
MEDPACE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
Safirstein Law LLC Announces That A Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP)
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Highlights Class Action Against Medpace Holdings (MEDP) and Upcoming Lead Plaintiff Deadline of June 8, 2026
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Highlights Class Action Against Medpace Holdings (MEDP) and Upcoming Lead Plaintiff Deadline of June 8, 2026
INVESTOR DEADLINE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
MEDP DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
MEDP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
MEDP DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
MONDAY INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - MEDP